May 15 |
UPDATE 1-Eisai starts rolling submission for injectable version of Alzheimer's drug with US FDA
|
May 14 |
Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Under the Fast Track Status
|
May 14 |
Eisai starts rolling submission for injectable version of Alzheimer's drug with US FDA
|
May 13 |
15 Most Depressed States in the US
|
May 11 |
3 S&P 500 Stocks to Rival Nvidia’s 2023 Performance in the Second Half of 2024
|
May 9 |
The 3 Most Undervalued Pharma Stocks to Buy in May 2024
|
May 8 |
Jeff Auxier's Firm Dissolves Textainer Group Position, Trims Biogen
|
May 8 |
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
|
May 8 |
Q1 2024 Abcellera Biologics Inc Earnings Call
|
May 4 |
Morgan Stanley’s Top 15 Stock Picks for 2024
|